Slide 1: Rhythm Biosciences: An ASX Life Sciences Growth Opportunity
For personal use only Rhythm Biosciences An ASX Life Sciences Growth Opportunity 6 AUGUST 2026 – 20TH BIOSHARES BIOTECH SUMMIT
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, rep
Slide 3: Cancer is often detected too late
Cancer is often detected too late Earlier detection significantly improves survival outcomes and lowers treatment costs. For personal use only 15,500+ new colorectal cancer cases diagnosed every year in Australia >50% diagnosed as late-stage disease (Stages III or IV) 10% 5-year survival rate when d
Slide 4: Detecting cancer earlier saves lives
Detecting cancer earlier saves lives Two complementary platforms. One longitudinal precision cancer diagnostic strategy. For personal use only RISK ASSESSMENT DISEASE SCREENING Who is at risk? Who has the disease? Genomic cancer risk assessment that identifies Blood-based bowel cancer detection that
Slide 5: A blood-based colorectal cancer detection platform (ColoSTAT)
For personal use only A blood-based colorectal cancer detection platform designed to aid effective early diagnosis. www.colostat.com 4 © Rhythm Biosciences 2026
Slide 6: Million patients waiting on a colonoscopy decision
22 million patients waiting on a colonoscopy decision… ColoSTAT® OPPORTUNITY 1 OF 2 NEAR TERM 22M symptomatic patients could benefit from better- informed colonoscopy decisions. That’s approximately For personal use only 40% of annual colonoscopy volumes worldwide. Estimated annual triage An alterna
Slide 7: Million eligible people remain unscreened
…and 290 million eligible people remain unscreened. ColoSTAT® OPPORTUNITY 2 OF 2 LONG TERM For personal use only ~400 million ~290 million 3 in 4 people are eligible for people do not participate in remain unscreened bowel cancer screening recommended screening Estimated screening-age Most eligible
Slide 8: Scaling ColoSTAT through established clinical channels
Scaling ColoSTAT® through established clinical channels Clinically validated. Partner-enabled. Built for national scale. For personal use only AN ESTABLISHED MARKET A NATIONAL REFERRAL BASE EVIDENCE-LED ADOPTION >800,000 ~41,000 Clinical and colonoscopies performed primary care and specialist econom
Slide 9: Personalised cancer risk assessment (geneType)
For personal use only Personalised cancer risk assessment designed to support earlier detection and prevention. www.genetype.com 8 © Rhythm Biosciences 2026
Slide 10: Personalised cancer risk assessment at scale
Personalised cancer risk assessment at scale geneType CANCER RISK ASSESSMENT PLATFORM For personal use only How geneType reaches the market A broader cancer portfolio Six# cancer risk assessments, including three that complement Rhythm’s protein biomarker programs. Clinics – 25% 25% Direct volume. H
Slide 11: Rhythm Biosciences at a glance
Rhythm Biosciences at a glance Building a scalable precision diagnostics platform For personal use only CORPORATE SNAPSHOT 5 JUNE 2026 Personalised cancer risk assessment designed to ASX Code RHY support earlier detection and prevention. Share Price $0.086 RISK ASSESSMENT www.genetype.com Shares on
Slide 12: FY27 Catalysts
FY27 Catalysts Positioned for the next phase of commercial expansion and international growth. For personal use only PRODUCT ITEM DESCRIPTION COMPLETION DATE ColoSTAT® Scaling commercial footprint Activation of additional 4Cyte collection centres Q1 FY27 geneType strategic Establishment of key inter
Slide 13: Team
Team Experienced diagnostics leadership executing the next phase of commercial growth For personal use only Jackson Jones Gary Goh Chief Commercial Officer Head of Laboratory David Atkins, PhD Sue MacLeman Gavin Fox-Smith Operations and RA/QA CEO & MD Non-Executive Director Non-Executive Director Fo
Slide 14: Why Rhythm Biosciences? Why now?
Why Rhythm Biosciences? Why now? For personal use only Dual-platform precision diagnostics strategy Longitudinal disease management: Combining personalised risk assessment and earlier cancer detection. Commercialisation underway Development risks largely retired. Commercial validation, partnerships
Slide 15: Thank you!
For personal use only Thank you! David Atkins, PhD david.atkins@rhythmbio.com www.rhythmbio.com